End-of-day quote
Korea S.E.
07:00:00 2024-03-28 pm EDT
|
5-day change
|
1st Jan Change
|
412
KRW
|
+26.77%
|
|
-.--%
|
-64.17%
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
72,522
|
50,066
|
88,148
|
278,876
|
157,032
|
63,643
|
Enterprise Value (EV)
1 |
53,234
|
31,935
|
79,567
|
270,999
|
204,847
|
136,357
|
P/E ratio
|
17.7
x
|
14.5
x
|
190
x
|
-47.2
x
|
-1.35
x
|
-2.75
x
|
Yield
|
-
|
1.33%
|
0.73%
|
-
|
-
|
-
|
Capitalization / Revenue
|
4.89
x
|
3.08
x
|
5.84
x
|
15.5
x
|
9.76
x
|
3.54
x
|
EV / Revenue
|
3.59
x
|
1.97
x
|
5.27
x
|
15
x
|
12.7
x
|
7.58
x
|
EV / EBITDA
|
13.1
x
|
6.33
x
|
68.4
x
|
-227
x
|
1,048
x
|
101
x
|
EV / FCF
|
-129
x
|
-6.24
x
|
-30.7
x
|
-77.7
x
|
9.71
x
|
-12.8
x
|
FCF Yield
|
-0.78%
|
-16%
|
-3.26%
|
-1.29%
|
10.3%
|
-7.78%
|
Price to Book
|
1.66
x
|
1.08
x
|
1.96
x
|
5.02
x
|
5.89
x
|
3.68
x
|
Nbr of stocks (in thousands)
|
33,889
|
33,289
|
32,289
|
39,669
|
54,810
|
55,342
|
Reference price
2 |
2,140
|
1,504
|
2,730
|
7,030
|
2,865
|
1,150
|
Announcement Date
|
3/21/19
|
3/19/20
|
3/23/21
|
3/21/22
|
3/29/24
|
3/29/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
14,833
|
16,230
|
15,098
|
18,021
|
16,083
|
17,992
|
EBITDA
1 |
4,062
|
5,046
|
1,163
|
-1,192
|
195.4
|
1,349
|
EBIT
1 |
3,121
|
3,680
|
-636.2
|
-2,501
|
-1,226
|
-340.4
|
Operating Margin
|
21.04%
|
22.68%
|
-4.21%
|
-13.88%
|
-7.62%
|
-1.89%
|
Earnings before Tax (EBT)
1 |
4,357
|
3,704
|
-114.7
|
-5,209
|
-91,272
|
-25,393
|
Net income
1 |
3,787
|
3,464
|
470
|
-5,192
|
-91,982
|
-23,087
|
Net margin
|
25.53%
|
21.34%
|
3.11%
|
-28.81%
|
-571.92%
|
-128.32%
|
EPS
2 |
121.1
|
104.0
|
14.40
|
-149.0
|
-2,123
|
-418.0
|
Free Cash Flow
1 |
-413.9
|
-5,118
|
-2,593
|
-3,488
|
21,094
|
-10,612
|
FCF margin
|
-2.79%
|
-31.54%
|
-17.17%
|
-19.36%
|
131.16%
|
-58.98%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
10,794.04%
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
20.00
|
20.00
|
-
|
-
|
-
|
Announcement Date
|
3/21/19
|
3/19/20
|
3/23/21
|
3/21/22
|
3/29/24
|
3/29/24
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
47,816
|
72,714
|
Net Cash position
1 |
19,288
|
18,131
|
8,581
|
7,877
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
244.7
x
|
53.9
x
|
Free Cash Flow
1 |
-414
|
-5,118
|
-2,593
|
-3,488
|
21,094
|
-10,612
|
ROE (net income / shareholders' equity)
|
11.1%
|
6.91%
|
1.02%
|
-11.6%
|
-222%
|
-105%
|
ROA (Net income/ Total Assets)
|
5.41%
|
4.8%
|
-0.77%
|
-2.15%
|
-0.67%
|
-0.16%
|
Assets
1 |
70,019
|
72,175
|
-61,151
|
241,158
|
13,773,858
|
14,077,258
|
Book Value Per Share
2 |
1,288
|
1,389
|
1,391
|
1,402
|
487.0
|
312.0
|
Cash Flow per Share
2 |
142.0
|
78.60
|
96.30
|
550.0
|
48.40
|
58.70
|
Capex
1 |
1,416
|
7,990
|
1,430
|
4,594
|
885
|
1,966
|
Capex / Sales
|
9.54%
|
49.23%
|
9.47%
|
25.5%
|
5.5%
|
10.93%
|
Announcement Date
|
3/21/19
|
3/19/20
|
3/23/21
|
3/21/22
|
3/29/24
|
3/29/24
|
|
1st Jan change
|
Capi.
|
---|
| -64.17% | 16.8M | | -30.09% | 3.15B | | -15.57% | 2.57B | | +21.75% | 2.55B | | +7.04% | 2.09B | | -1.13% | 2.04B | | -0.56% | 1.53B | | +0.72% | 1.33B | | +23.78% | 1.23B | | +4.43% | 1.16B |
Medical Supplies
|